developed PD‐1 presenting nanovesicles to block massive PD‐L1 on tumor cells.[83] Also transgenic therapy, such cell‐free formulations listed here introduces no artificial vector and will undoubtedly improve the safety and controllability of clinical transformation. The gene discussed is CD274; the disease is neoplasm.